Zimbabwe has rejected a substantial American health deal valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's insistence on confidential data.
The decision was revealed after a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
A government representative later stated that the US was demanding access to biological samples for scientific study and commercial gain while was unwilling to guarantee the benefits from any future treatments.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued talks to find a deal agreeable to all parties so the nation's vital HIV treatment initiative can be sustained.
Broader Background
Zimbabwe's decision follows a similar situation in Kenya, where a court suspended a related deal with the US following legal challenges were raised about the security of Kenyans' health data.
Since returning to office last year, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost openness and responsibility.
Based on reports, 16 African countries have to date signed similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation could have provided extraordinary benefits for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to surrender its genetic material and health information indefinitely, without any corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"In essence, our country would provide the raw materials for scientific discovery without any certainty that the end products would be available to our citizens if a new health crisis emerge."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were disrupting systems already set up through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with future global health emergencies.
"This mechanism is intended to ensure that when a country contributes its data, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how subsequent co-operation might be designed in a manner that respects the sovereignty and interests of each country."
Health Experts Response
A leading public health body stated it recognised the official position, but suggested that negotiations must proceed given that much of the nation's HIV programmes relied on international support.
"In cases where technical issues arise, such as those relating to data governance or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," the group said.
The situation underscores the continuing challenges between accepting vital international aid and safeguarding a country's data in an increasingly data-driven world.